Method for diagnosing neoplasms
AssigneeB.R.A.H.M.S GmbH
InventorAndreas Bergmann
Life of this patent
Estimating the term…
Abstract
Disclosed are uses of Gangliosides GM1 and/or asialo-GM1 substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1 antibodies and/or anti-ADM1antibodies for producing agents which bind or block anti-GM1 antibodies and/or anti-AGM1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-GM1 antibodies and/or anti-AGM1 antibodies in order to prevent, inhibit, and treat malignant cancers.
Claims3
A method for the early diagnosis of cancer in a patient, said method comprising determining the amount of anti-asialoGM1 (AGM1) antibodies of the IgG and/or IgA type in a biological sample from a patient in whom cancer is suspected wherein said cancer is selected from the group comprising a carcinoma of the colon, a carcinoma of the breast, an ovarian carcinoma, a carcinoma of the pancreas, a carcinoma of the oesophagus, a carcinoma of the gall bladder, a carcinoma of the liver, a C cell carcinoma, a carcinoma of the thyroid, a carcinoma of the prostate, a carcinoma of the lung, a carcinoma of the appendix, a carcinoma of the bladder, a cardiac carcinoma, a carcinoma of the distal oesophagus, a carcinoma of the floor of the mouth, and a carcinoma of the kidney, wherein increased amounts of said antibodies compared with normal persons indicates the presence of cancer.
Dependencies are inferred from the claim text.